Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.37 |
| ▸ | TAS1R3 | Q7RTX0 | 2/20 | 0.36 |
| ▸ | TAS1R1 | Q7RTX1 | 2/20 | 0.36 |
| ▸ | P2RY12 | Q9H244 | 8/20 | 0.34 |
| ▸ | PRMT6 | Q96LA8 | 1/20 | 0.34 |
| ▸ | STING1 | Q86WV6 | 1/20 | 0.32 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.32 |
| ▸ | GAPDH | P04406 | 1/20 | 0.32 |
| ▸ | P2RY2 | P41231 | 1/20 | 0.32 |
| ▸ | P2RY1 | P47900 | 1/20 | 0.32 |
| ▸ | P2RY6 | Q15077 | 1/20 | 0.32 |
| ▸ | DNPH1 | O43598 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18490510 | 0.97 | KDM4E (0.37) | KDM4ETAS1R3TAS1R1P2RY12PRMT6 | |
| SCHEMBL22301419 | 0.97 | KDM4E (0.39) | KDM4ETAS1R3TAS1R1P2RY12PRMT6 | |
| SCHEMBL18917302 | 0.95 | KDM4E (0.37) | KDM4ETAS1R3TAS1R1P2RY12PRMT6 | |
| SCHEMBL18917307 | 0.95 | KDM4E (0.37) | KDM4ETAS1R3TAS1R1P2RY12PRMT6 | |
| SCHEMBL22301424 | 0.94 | KDM4E (0.39) | KDM4ETAS1R3TAS1R1P2RY12PRMT6 | |
| SCHEMBL22034291 | 0.93 | KDM4E (0.36) | KDM4ETAS1R3TAS1R1P2RY12PRMT6 | |
| SCHEMBL19762769 | 0.91 | KDM4E (0.38) | KDM4ETAS1R3TAS1R1P2RY12PRMT6 | |
| SCHEMBL18490411 | 0.91 | KDM4E (0.40) | KDM4ETAS1R3TAS1R1P2RY12PRMT6 | |
| SCHEMBL18490592 | 0.90 | TYMP (0.37) | KDM4ETAS1R3TAS1R1P2RY12PRMT6 | |
| SCHEMBL17860500 | 0.90 | TAS1R3 (0.41) | KDM4ETAS1R3TAS1R1P2RY12GAPDH |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10766919-B2 | Cyclic di-nucleotide compounds as sting agonists | MERCK SHARP & DOHME CORP. (US) | 2020-09-08 | — | — | US | disclosed |
| US-10759825-B2 | Cyclic di-nucleotide compounds as STING agonists | MERCK SHARP & DOHME CORP. (US) | 2020-09-01 | — | — | US | disclosed |
| US-10106574-B2 | Cyclic di-nucleotide compounds as sting agonists | MERCK SHARP & DOHME CORP. (US) | 2018-10-23 | — | — | US | disclosed |
| US-20180244712-A1 | CYCLIC DI-NUCLEOTIDE COMPOUNDS AS STING AGONISTS | MERCK SHARP & DOHME CORP. (US) | 2018-08-30 | — | — | US | disclosed |
| US-20180237469-A1 | CYCLIC DI-NUCLEOTIDE COMPOUNDS AS STING AGONISTS | MERCK SHARP & DOHME CORP. (US) | 2018-08-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10106574-B2 | Cyclic di-nucleotide compounds as sting agonists | STING1, CGAS, IFNAR1 | KDM4E 4116/4885TAS1R3 453/4885TAS1R1 161/4885 |
| US-20180237469-A1 | CYCLIC DI-NUCLEOTIDE COMPOUNDS AS STING AGONISTS | STING1, CGAS, IFNAR1 | KDM4E 4116/4885TAS1R3 453/4885TAS1R1 161/4885 |
| US-10766919-B2 | Cyclic di-nucleotide compounds as sting agonists | STING1, CGAS, IFNAR1 | KDM4E 4116/4885TAS1R3 453/4885TAS1R1 161/4885 |
| US-20180244712-A1 | CYCLIC DI-NUCLEOTIDE COMPOUNDS AS STING AGONISTS | STING1, CGAS, IFNAR1 | KDM4E 4116/4885TAS1R3 453/4885TAS1R1 161/4885 |
| US-10759825-B2 | Cyclic di-nucleotide compounds as STING agonists | STING1, CGAS, IFNAR1 | KDM4E 4116/4885TAS1R3 453/4885TAS1R1 161/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.